
1. General Information
Darzalex Faspro is a combination of daratumumab, a CD38-directed monoclonal antibody, and hyaluronidase-fihj, an enzyme that facilitates subcutaneous administration.
It is a specialist-administered prescription medicine used as part of established oncology treatment regimens. It should only be used under the supervision of a qualified oncologist or other appropriately trained healthcare professional.
For Phoenix Exim, the product can be described as a pharmaceutical oncology product supplied from Nagpur, India, subject to applicable export, import, prescription, and regulatory requirements in the destination country.
2. Product Information
- Brand: Darzalex Faspro
- Active ingredients: Daratumumab + hyaluronidase-fihj
- Strength: 1,800 mg daratumumab + 30,000 units hyaluronidase-fihj
- Pack volume: 15 mL single-dose vial
- Route: Subcutaneous
- Dosage form: Injection
- Therapeutic area: Oncology / hematology
- Drug class: CD38-directed monoclonal antibody combination
- Storage: Store according to the manufacturer's approved product labeling and cold-chain requirements.
3. Uses of Darzalex Faspro
Darzalex Faspro is used in combination with other medicines for particular adult patients with multiple myeloma. Depending on the treatment setting, approved combinations include regimens containing medicines such as bortezomib, lenalidomide, dexamethasone, pomalidomide, carfilzomib, or other specified agents.
It is also approved in combination with bortezomib, cyclophosphamide and dexamethasone for certain adults with newly diagnosed light-chain (AL) amyloidosis.
4. Benefits of This Medicine
Potential clinical benefits include:
- Helps target CD38-expressing malignant plasma cells.
- Can contribute to reduction of abnormal plasma-cell activity in multiple myeloma.
- Provides an additional targeted treatment option within combination therapy.
- The subcutaneous formulation can allow administration in a relatively short period compared with traditional intravenous administration of daratumumab.
- Hyaluronidase facilitates dispersion and absorption of the medicine through subcutaneous tissue.
The expected benefit varies according to the patient's disease status, treatment regimen and previous therapies.
5. Side Effects
Darzalex Faspro can cause adverse reactions, including potentially serious reactions. Important risks include:
- Administration-related or hypersensitivity reactions
- Decreased white blood cells/neutrophils
- Decreased platelets
- Increased risk of infections
- Injection-site reactions
- Respiratory symptoms
- Fatigue
- Gastrointestinal symptoms
In patients with AL amyloidosis and cardiac involvement, particular attention to cardiac toxicity is required.
6. Common Side Effects
Depending on the treatment combination, commonly reported adverse reactions can include:
- Upper respiratory tract infection
- Fatigue
- Diarrhea
- Constipation
- Nausea
- Cough
- Fever
- Pneumonia
- Shortness of breath
- Muscle spasms
- Insomnia
- Peripheral edema
- Peripheral sensory neuropathy
- Headache
The exact frequency and side-effect profile depend on the combination regimen being used.
7. How to Use
Darzalex Faspro is not a self-administered medicine. It should be prepared and administered by a healthcare professional familiar with oncology medicines.
The recommended 1,800-mg dose contains 1,800 mg daratumumab and 30,000 units hyaluronidase and is administered subcutaneously into the abdomen over approximately 3–5 minutes, according to the treatment schedule prescribed for the specific indication.
Patients generally receive appropriate pre-medications, including a corticosteroid, acetaminophen and an antihistamine, to reduce the risk of administration-related reactions. Additional post-medications may also be prescribed.
8. How This Medicine Works
Daratumumab binds to CD38, a protein expressed on the surface of plasma cells, including malignant plasma cells associated with multiple myeloma.
After binding to CD38, daratumumab can promote destruction of these cells through several immune-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Hyaluronidase-fihj temporarily increases permeability of the subcutaneous tissue, helping the medicine disperse and be absorbed after subcutaneous administration.
9. Safety Advice
- Use only under specialist medical supervision.
- Do not use in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or formulation components.
- Patients should be monitored for administration-related reactions.
- Blood counts should be monitored during treatment because neutropenia and thrombocytopenia can occur.
- Patients should be monitored for signs of infection.
- Patients receiving treatment for AL amyloidosis with cardiac involvement require particular monitoring.
- Daratumumab can interfere with blood compatibility testing/cross-matching. Patients should have appropriate blood typing and screening before treatment, and blood banks should be informed that the patient has received Darzalex Faspro.
- It can cause fetal harm; pregnancy and contraception considerations should be discussed with the treating healthcare professional.
10. FAQs
Q1. What is Darzalex Faspro 1800 mg?
It is a subcutaneous oncology injection containing 1,800 mg daratumumab and 30,000 units hyaluronidase-fihj in 15 mL.
Q2. What is Darzalex Faspro used for?
It is used in specified treatment regimens for adult patients with multiple myeloma and certain patients with light-chain (AL) amyloidosis.
Q3. Is Darzalex Faspro a chemotherapy medicine?
It is a targeted monoclonal antibody therapy, rather than a conventional cytotoxic chemotherapy drug.
Q4. How is Darzalex Faspro administered?
It is administered by subcutaneous injection into the abdomen by a healthcare professional.
Q5. Can patients administer it themselves?
Patients should not self-administer it unless specifically directed and trained under an approved treatment protocol. It is generally administered by healthcare professionals.
Q6. Can Darzalex Faspro be used alone?
Depending on the patient's treatment history and the applicable approved indication, daratumumab-containing therapy may be used as monotherapy or in combination with other medicines.
Q7. Does it require prescription?
Yes. It is a prescription oncology medicine requiring specialist supervision.
Q8. Can it affect blood transfusion testing?
Yes. Daratumumab can interfere with antibody screening and cross-matching, so the blood bank should be informed before transfusion-related testing.
11. Substitute for Darzalex Faspro
There is no universal one-to-one substitute that should be selected without considering the patient's diagnosis, treatment history and prescribed regimen.
Potentially related daratumumab-based alternatives include DARZALEX (daratumumab), which is an intravenous formulation, while other anti-CD38 therapies such as isatuximab may be considered in particular multiple-myeloma treatment settings. These are not automatically interchangeable with Darzalex Faspro and require a physician's decision.
A healthcare professional should select any alternative based on the approved indication and treatment protocol.
12. SEO Keywords
Primary keywords:
- Darzalex Faspro 1800 mg Injection
- Darzalex Faspro 1800 mg
- Daratumumab 1800 mg Injection
- Daratumumab Hyaluronidase Injection
- Darzalex Faspro Injection supplier
- Darzalex Faspro Injection exporter
- Darzalex Faspro pharmaceutical exporter
- Darzalex Faspro medicine exporter India
- Darzalex Faspro 1800 mg supplier India
- Daratumumab injection supplier India
B2B / export keywords:
- Darzalex Faspro 1800 mg exporter from Nagpur India
- Darzalex Faspro wholesale pharmaceutical supplier India
- Darzalex Faspro oncology medicine exporter
- Daratumumab oncology injection exporter India
- Darzalex Faspro bulk medicine supplier
- Darzalex Faspro international pharmaceutical supplier
- Darzalex Faspro supplier USA
- Darzalex Faspro supplier UK
- Darzalex Faspro supplier Australia
- Darzalex Faspro supplier Canada
- Darzalex Faspro supplier Singapore
- Darzalex Faspro supplier South Korea
- Darzalex Faspro supplier UAE
- Daratumumab injection exporter to USA
- Daratumumab injection exporter to UK
- Daratumumab injection exporter to Australia
- Daratumumab injection exporter to Canada
- Daratumumab injection exporter to Singapore
- Daratumumab injection exporter to South Korea
- Daratumumab injection exporter to UAE
- Phoenix Exim Darzalex Faspro supplier
- Phoenix Exim oncology medicine exporter
- Phoenix Exim pharmaceutical exporter Nagpur India
Keywords







